首页 > 市场调查报告书 > 医疗设备

美容整形

北美肉毒桿菌毒素市场预测至2031 年- 区域分析- 按产品（肉毒桿菌毒素A 和肉毒桿菌毒素B）、应用（医疗和美容）和最终用户（专科和皮肤科诊所、医院和诊所等）

市场调查报告书

商品编码

1592653

北美肉毒桿菌毒素市场预测至2031 年- 区域分析- 按产品（肉毒桿菌毒素A 和肉毒桿菌毒素B）、应用（医疗和美容）和最终用户（专科和皮肤科诊所、医院和诊所等）

North America Botulinum Toxin Market Forecast to 2031 - Regional Analysis - by Product (Botulinum Toxin A and Botulinum Toxin B), Application (Medical and Aesthetic), and End User (Specialty & Dermatology Clinics, Hospitals & Clinics, and Others)

出版日期: 2024年09月16日 | 出版商:

The Insight Partners | 英文 77 Pages | 订单完成后即时交付

价格

简介目录图表

2023年北美肉毒桿菌毒素市值为48.0129亿美元，预计到2031年将达到120.726亿美元；预计2023年至2031年复合年增长率为12.2%。

扩大治疗应用推动北美肉毒桿菌毒素市场

A 型和 B 型肉毒桿菌毒素可阻断神经肌肉和神经分泌接头处释放的囊泡乙酰胆碱，为需要神经復健介入的患者提供强大的治疗效果。根据临床报告，肉毒桿菌毒素已被证明对头痛、流涎和多汗症等具有治疗作用。肉毒桿菌治疗可以作为手术的替代方案。对于慢性肛裂患者来说，它似乎是括约肌切开术的一种有前途的替代方法。患有一些自主神经疾病（如垂涎欲滴或味觉出汗）和腺体分泌过多（患者接受腮腺手术后经常发生的情况）的患者对肉毒桿菌毒素反应良好。儘管辅助生殖技术领域取得了许多进步，但仍有相当多的患者反覆遭受着床失败的困扰。子宫内膜的充分生长对于辅助生殖过程中的胚胎着床和怀孕持续起着至关重要的作用。多年来，肉毒桿菌毒素已广泛应用于整形和美容手术；研究表明，肉毒桿菌毒素对人类角质形成细胞的上皮再形成和内皮细胞的血管生成有正面影响。临床结果表明，肉毒桿菌毒素透过增加细胞增殖和血管形成，减少胶原蛋白累积病变，促进薄子宫内膜受损结构和受损功能的恢復，最终有助于胚胎成功植入。因此，肉毒桿菌治疗应用的不断扩大可能会在未来几年带来新的肉毒桿菌毒素市场趋势。

北美肉毒毒素市场概况

北美肉毒桿菌毒素市场分为美国、加拿大和墨西哥。北美市场的成长主要与经济稳定的人口以及上述国家进行的非手术或微创美容手术数量的增加有关。透过注射肉毒桿菌毒素减少脸部皱纹是美国最常进行的美容手术。对于愿意将美容疗程纳入其实践的临床医生来说，这是最常见的入门手术之一。根据国际美容整形外科学会（ISAPS）统计，2021年美国进行了近250万例肉毒桿菌毒素手术。可预测的结果，副作用很少，病人满意度高。 Allergan 的 BOTOX Cosmetic/Vistabel、Galderma 和 Ipsen 的 Dysport/Azzalure、Merz 的 Xeomin/Bocouture 和 Evolus 的 Jeuveau（仅由 Daewoong 为美国生产）是该国市售的肉毒毒素产品。美国 FDA 已批准 BOTOX 化妆品适用于 18-65 岁年龄层的人。据美国美容整形外科协会称，肉毒桿菌注射是美容行业中成长最快的手术。 2023年8月，Daxxify（daxibotulinumtoxinA-lanm）被FDA核准为治疗成人颈部肌张力失调的第一个治疗适应症。颈部肌张力失调的特征是颈部肌肉无法控制地发生痉挛或收缩，导致异常运动、姿势不当、头颈部疼痛。这种情况影响了大约 6 万名美国人。注射肉毒桿菌毒素有利于颈部肌张力失调患者受影响的肌肉放鬆，进而减少僵硬和痉挛。然而，治疗效果会慢慢消失，因此患者需要频繁復治。此前，2021年7月，FDA批准了艾伯维公司旗下艾尔建公司BOTOX Cosmetic的标籤扩展。艾尔建 (Allergan) 扩大了 BOTOX 的应用范围，可治疗 8 种与成人上肢痉挛相关的新肌肉疾病。

北美肉毒桿菌毒素市场收入及 2031 年预测（百万美元）

北美肉毒毒素市场细分

北美肉毒桿菌毒素市场按产品、应用、最终用户和国家分类。

根据产品，北美肉毒桿菌毒素市场分为肉毒桿菌毒素A和肉毒桿菌毒素B。

从应用来看，北美肉毒桿菌市场分为医疗和美容。 2023年，医疗领域在北美肉毒桿菌毒素市场中占据较大份额。此外，美感部分也细分为皱眉纹/眉间纹、额头纹、鱼尾纹、方下巴/咬肌等。

依最终用户划分，北美肉毒桿菌市场分为专科和皮肤科诊所、医院和诊所等。 2023 年，专科诊所和皮肤科诊所占据北美肉毒桿菌市场的最大份额。

按国家/地区划分，北美肉毒桿菌市场分为美国、加拿大和墨西哥。 2023年，美国在北美肉毒桿菌毒素市场份额中占据主导地位。

Merz Pharma GmbH & Co KGaA、AbbVie Inc、Ipsen SA、Evolus Inc、Aquavit、Revance Therapeutics Inc、Medytox Inc、Galderma SA、Hugel Inc 和兰州生物製品研究所有限公司是在北美运营的一些领先公司肉毒毒素市场。

The botulinum toxins type A and B block vesicular acetylcholine released at neuromuscular and neurosecretory junctions, thereby delivering powerful therapeutic outcomes for treating patients requiring neurorehabilitation intervention. As per clinical reports, botulinum toxins have been proven to have therapeutic effects against headache, salivate, and hyperhidrosis, among others. Botulinum treatment can be adopted as an alternative to surgery. It appears to be a promising alternative to sphincterotomy in patients with chronic anal fissures. Patients suffering from a few autonomic disorders such as ptyalism or gustatory sweating, and hypersecretion of glands (a condition that often occurs after patients undergo surgeries involving parotid glands) respond well to botulinum toxins. Despite numerous advancements in the field of assisted reproductive technology, a significant number of patients still suffer from repeated implantation failure. Adequate endometrial growth plays a crucial role in embryo implantation and pregnancy continuation in an assisted reproductive procedure. For several years, botulinum toxins have been widely used in plastic and aesthetic surgeries; it has been revealed that botulinum toxins have a positive influence on the re-epithelialization of human keratinocytes and the angiogenesis of endothelial cells. Clinical results reveal that botulinum toxin administration facilitates the recovery of damaged structure and impaired function of the thin endometrium by increasing cellular proliferation and vessel formation, reducing collagen-accumulated lesions, and ultimately contributing to successful embryo implantation. Thus, the expanding therapeutic applications of botulinum toxins are likely to bring new botulinum toxins market trends in the coming years.

North America Botulinum Toxin Market Overview

The North America botulinum toxin market is segmented into the US, Canada, and Mexico. The market growth in North America can be mainly associated with the economically stable population and increasing numbers of nonsurgical or minimally invasive cosmetic procedures performed in the abovementioned countries. Reduction of facial wrinkles with botulinum toxin injections is the most performed cosmetic procedure in the US. It is one of the most common entry-level procedures for clinicians willing to incorporate aesthetic treatments into their practice. According to the International Society of Aesthetic Plastic Surgery (ISAPS), nearly 2.5 million botulinum toxin procedures were performed in the US in 2021. The treatment of frown lines and crow's feet approved by the US Food and Drug Administration- for cosmetic indications and horizontal forehead wrinkles provide predictable results, have few side effects, and high patient satisfaction. BOTOX Cosmetic/Vistabel by Allergan, Dysport/Azzalure by Galderma and Ipsen, Xeomin/Bocouture by Merz, and Jeuveau by Evolus (manufactured only by Daewoong for the US) are among the commercially available botulinum toxin products in the country. The US FDA has approved BOTOX Cosmetic for people from the age range of 18-65. According to the American Society for Aesthetic Plastic Surgery, botox injection is the fastest-growing procedure in the cosmetic industry. In August 2023, Daxxify (daxibotulinumtoxinA-lanm) was approved by the FDA as the first therapeutic indication to treat adult cervical dystonia. Cervical dystonia is characterized by uncontrollably occurring spasms or contractions in neck muscles, causing unusual movements, awkward posture, and head and neck pain. This condition affects approximately 60,000 Americans. The injection of botulinum toxin facilitates the relaxation of affected muscles in cervical dystonia patients, thereby reducing stiffness and spasms. However, the effect of the treatment slowly wears off, and thus, patients need frequent retreatments. Earlier, in July 2021, the FDA approved the label expansion of BOTOX Cosmetic of Allergan, an AbbVie company. Allergan has expanded BOTOX's applications to treat 8 new muscle conditions related to upper limb spasticity in adults.

North America Botulinum Toxin Market Revenue and Forecast to 2031 (US$ Million)

North America Botulinum Toxin Market Segmentation

The North America botulinum toxin market is categorized into product, application, end user, and country.

Based on product, the North America botulinum toxin market is bifurcated into botulinum toxin A and botulinum toxin B. The botulinum toxin A segment held the larger share of North America botulinum toxin market share in 2023.

In terms of application, the North America botulinum toxin market is bifurcated into medical and aesthetic. The medical segment held the larger share of North America botulinum toxin market in 2023. Furthermore, the medical segment is subcategorized into chronic migraine, muscle spasm, over reactive bladder, hyperhidrosis, and others. Additionally, the aesthetic segment is subcategorized into frown lines/ glabellar, forehead lines, crow's feet, square jaw/ masseter, and others.

By end user, the North America botulinum toxin market is divided into specialty & dermatology clinics, hospitals & clinics, and others. The specialty and dermatology clinics segment held the largest share of North America botulinum toxin market in 2023.

Based on country, the North America botulinum toxin market is segmented into the US, Canada, and Mexico. The US dominated the North America botulinum toxin market share in 2023.

Merz Pharma GmbH & Co KGaA, AbbVie Inc, Ipsen SA, Evolus Inc, Aquavit, Revance Therapeutics Inc, Medytox Inc, Galderma SA, Hugel Inc, and Lanzhou Institute of Biological Products Co Ltd are some of the leading companies operating in the North America botulinum toxin market.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. North America Botulinum Toxin Market - Key Market Dynamics

4.1 Market Drivers
- 4.1.1 Rising Popularity of Noninvasive Aesthetics Procedures
- 4.1.2 Increasing Use of Botulinum Toxin for Enhancing Facial Aesthetics
4.2 Market Restraints
- 4.2.1 Side Effects of Botulinum Toxin
4.3 Market Opportunities
- 4.3.1 Rising Adoption of Aesthetic Procedure in Emerging Economies
4.4 Future Trends
- 4.4.1 Expanding Therapeutic Applications
4.5 Impact of Drivers and Restraints:

5. Botulinum Toxin Market - North America Analysis

5.1 Overview
5.2 Botulinum Toxin Market Revenue (US$ Million), 2021-2031

6. North America Botulinum Toxin Market Analysis - by Product

6.1 Overview
6.2 Botulinum Toxin A
- 6.2.1 Overview
- 6.2.2 Botulinum Toxin A: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
6.3 Botulinum Toxin B
- 6.3.1 Overview
- 6.3.2 Botulinum Toxin B: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)

7. North America Botulinum Toxin Market Analysis - by Application

7.1 Overview
7.2 Medical
- 7.2.1 Overview
- 7.2.2 Medical: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
  - 7.2.2.1 North America Botulinum Toxin Market Breakdown, by Medical
7.3 Aesthetic
- 7.3.1 Overview
- 7.3.2 Aesthetic: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
  - 7.3.2.1 North America Botulinum Toxin Market Breakdown, by Aesthetic

8. North America Botulinum Toxin Market Analysis - by End User

8.1 Overview
8.2 Specialty and Dermatology Clinics
- 8.2.1 Overview
- 8.2.2 Specialty and Dermatology Clinics: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Hospitals and Clinics
- 8.3.1 Overview
- 8.3.2 Hospitals and Clinics: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
8.4 Others
- 8.4.1 Overview
- 8.4.2 Others: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)

9. North America Botulinum Toxin Market - Country Analysis

9.1 North America: Botulinum Toxin Market
- 9.1.1 North America: Botulinum Toxin Market - Revenue and Forecast Analysis - by Country
  - 9.1.1.1 United States: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.1.1.1.1 Overview
    - 9.1.1.1.2 United States: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.1.1.1.3 United States: Botulinum Toxin Market Breakdown, by Product
    - 9.1.1.1.4 United States: Botulinum Toxin Market Breakdown, by Application
    - 9.1.1.1.4.1 United States: Botulinum Toxin Market Breakdown, by Medical
    - 9.1.1.1.4.2 United States: Botulinum Toxin Market Breakdown, by Aesthetic
    - 9.1.1.1.5 United States: Botulinum Toxin Market Breakdown, by End User
  - 9.1.1.2 Canada: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.1.1.2.1 Overview
    - 9.1.1.2.2 Canada: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.1.1.2.3 Canada: Botulinum Toxin Market Breakdown, by Product
    - 9.1.1.2.4 Canada: Botulinum Toxin Market Breakdown, by Application
    - 9.1.1.2.4.1 Canada: Botulinum Toxin Market Breakdown, by Medical
    - 9.1.1.2.4.2 Canada: Botulinum Toxin Market Breakdown, by Aesthetic
    - 9.1.1.2.5 Canada: Botulinum Toxin Market Breakdown, by End User
  - 9.1.1.3 Mexico: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.1.1.3.1 Overview
    - 9.1.1.3.2 Mexico: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.1.1.3.3 Mexico: Botulinum Toxin Market Breakdown, by Product
    - 9.1.1.3.4 Mexico: Botulinum Toxin Market Breakdown, by Application
    - 9.1.1.3.4.1 Mexico: Botulinum Toxin Market Breakdown, by Medical
    - 9.1.1.3.4.2 Mexico: Botulinum Toxin Market Breakdown, by Aesthetic
    - 9.1.1.3.5 Mexico: Botulinum Toxin Market Breakdown, by End User

10. Company Profiles

10.1 Merz Pharma GmbH & Co KGaA
- 10.1.1 Key Facts
- 10.1.2 Business Description
- 10.1.3 Products and Services
- 10.1.4 Financial Overview
- 10.1.5 SWOT Analysis
- 10.1.6 Key Developments
10.2 AbbVie Inc
- 10.2.1 Key Facts
- 10.2.2 Business Description
- 10.2.3 Products and Services
- 10.2.4 Financial Overview
- 10.2.5 SWOT Analysis
- 10.2.6 Key Developments
10.3 Ipsen SA
- 10.3.1 Key Facts
- 10.3.2 Business Description
- 10.3.3 Products and Services
- 10.3.4 Financial Overview
- 10.3.5 SWOT Analysis
- 10.3.6 Key Developments
10.4 Evolus Inc
- 10.4.1 Key Facts
- 10.4.2 Business Description
- 10.4.3 Products and Services
- 10.4.4 Financial Overview
- 10.4.5 SWOT Analysis
- 10.4.6 Key Developments
10.5 Aquavit
- 10.5.1 Key Facts
- 10.5.2 Business Description
- 10.5.3 Products and Services
- 10.5.4 Financial Overview
- 10.5.5 SWOT Analysis
- 10.5.6 Key Developments
10.6 Revance Therapeutics Inc
- 10.6.1 Key Facts
- 10.6.2 Business Description
- 10.6.3 Products and Services
- 10.6.4 Financial Overview
- 10.6.5 SWOT Analysis
- 10.6.6 Key Developments
10.7 Medytox Inc
- 10.7.1 Key Facts
- 10.7.2 Business Description
- 10.7.3 Products and Services
- 10.7.4 Financial Overview
- 10.7.5 SWOT Analysis
- 10.7.6 Key Developments
10.8 Galderma SA
- 10.8.1 Key Facts
- 10.8.2 Business Description
- 10.8.3 Products and Services
- 10.8.4 Financial Overview
- 10.8.5 SWOT Analysis
- 10.8.6 Key Developments
10.9 Hugel Inc
- 10.9.1 Key Facts
- 10.9.2 Business Description
- 10.9.3 Products and Services
- 10.9.4 Financial Overview
- 10.9.5 SWOT Analysis
- 10.9.6 Key Developments
10.10 Lanzhou Institute of Biological Products Co Ltd
- 10.10.1 Key Facts
- 10.10.2 Business Description
- 10.10.3 Products and Services
- 10.10.4 Financial Overview
- 10.10.5 SWOT Analysis
- 10.10.6 Key Developments

11. Appendix

11.1 About The Insight Partners

简介目录图表

List Of Tables

Table 1. Botulinum Toxin Market Segmentation
Table 2. North America Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Medical
Table 3. North America Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Aesthetic
Table 4. United States: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Product
Table 5. United States: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Application
Table 6. United States: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Medical
Table 7. United States: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Aesthetic
Table 8. United States: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 9. Canada: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Product
Table 10. Canada: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Application
Table 11. Canada: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Medical
Table 12. Canada: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Aesthetic
Table 13. Canada: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 14. Mexico: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Product
Table 15. Mexico: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Application
Table 16. Mexico: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Medical
Table 17. Mexico: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Aesthetic
Table 18. Mexico: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 19. Glossary of Terms

List Of Figures

Figure 1. Botulinum Toxin Market Segmentation, by Country
Figure 2. Botulinum Toxin Market - Key Market Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Botulinum Toxin Market Revenue (US$ Million), 2021-2031
Figure 5. Botulinum Toxin Market Share (%) - by Product (2023 and 2031)
Figure 6. Botulinum Toxin A: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
Figure 7. Botulinum Toxin B: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
Figure 8. Botulinum Toxin Market Share (%) - by Application (2023 and 2031)
Figure 9. Medical: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
Figure 10. Aesthetic: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
Figure 11. Botulinum Toxin Market Share (%) - by End User (2023 and 2031)
Figure 12. Specialty and Dermatology Clinics: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
Figure 13. Hospitals and Clinics: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
Figure 14. Others: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
Figure 15. North America: Botulinum Toxin Market, by Key Country - Revenue (2023) (US$ Million)
Figure 16. North America: Botulinum Toxin Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 17. United States: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
Figure 18. Canada: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
Figure 19. Mexico: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)